70 related articles for article (PubMed ID: 23999041)
21. Estrogens do not modify MAP kinase-dependent nuclear signaling during stimulation of early G(1) progression in human breast cancer cells.
Caristi S; Galera JL; Matarese F; Imai M; Caporali S; Cancemi M; Altucci L; Cicatiello L; Teti D; Bresciani F; Weisz A
Cancer Res; 2001 Sep; 61(17):6360-6. PubMed ID: 11522626
[TBL] [Abstract][Full Text] [Related]
22. Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation.
Liu Y; Hock JM; Sullivan C; Fang G; Cox AJ; Davis KT; Davis BH; Li X
J Cell Biochem; 2010 Dec; 111(6):1546-55. PubMed ID: 20862710
[TBL] [Abstract][Full Text] [Related]
23. Asiatic acid, a triterpene, induces apoptosis and cell cycle arrest through activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways in human breast cancer cells.
Hsu YL; Kuo PL; Lin LT; Lin CC
J Pharmacol Exp Ther; 2005 Apr; 313(1):333-44. PubMed ID: 15626723
[TBL] [Abstract][Full Text] [Related]
24. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
26. Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation.
Duhamel S; Hébert J; Gaboury L; Bouchard A; Simon R; Sauter G; Basik M; Meloche S
Cancer Res; 2012 Feb; 72(3):626-35. PubMed ID: 22298595
[TBL] [Abstract][Full Text] [Related]
27. Extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression.
Yang W; Chen Y; Zhang Y; Wang X; Yang N; Zhu D
Cancer Res; 2006 Feb; 66(3):1320-6. PubMed ID: 16452185
[TBL] [Abstract][Full Text] [Related]
28. A bidirectional "alpha(v)beta(3) integrin-ERK1/ERK2 MAPK" connection regulates the proliferation of breast cancer cells.
Vellon L; Menendez JA; Lupu R
Mol Carcinog; 2006 Oct; 45(10):795-804. PubMed ID: 16705745
[TBL] [Abstract][Full Text] [Related]
29. Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation.
Ye Y; Hou R; Chen J; Mo L; Zhang J; Huang Y; Mo Z
Horm Metab Res; 2012 Apr; 44(4):263-7. PubMed ID: 22328166
[TBL] [Abstract][Full Text] [Related]
30. Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation.
Noman AS; Koide N; Khuda II; Dagvadorj J; Tumurkhuu G; Naiki Y; Komatsu T; Yoshida T; Yokochi T
Biochem Biophys Res Commun; 2008 Oct; 374(4):683-7. PubMed ID: 18662673
[TBL] [Abstract][Full Text] [Related]
31. Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway.
Karam M; Legay C; Auclair C; Ricort JM
Exp Cell Res; 2012 Mar; 318(5):558-69. PubMed ID: 22245102
[TBL] [Abstract][Full Text] [Related]
32. The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways.
Kim CK; Choi YK; Lee H; Ha KS; Won MH; Kwon YG; Kim YM
Mol Pharmacol; 2010 Jul; 78(1):142-50. PubMed ID: 20406854
[TBL] [Abstract][Full Text] [Related]
33. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
34. TLN-4601, a novel anticancer agent, inhibits Ras signaling post Ras prenylation and before MEK activation.
Boufaied N; Wioland MA; Falardeau P; Gourdeau H
Anticancer Drugs; 2010 Jun; 21(5):543-52. PubMed ID: 20220516
[TBL] [Abstract][Full Text] [Related]
35. ERK-modulated intrinsic signaling and G(2)/M phase arrest contribute to the induction of apoptotic death by allyl isothiocyanate in MDA-MB-468 human breast adenocarcinoma cells.
Tsai SC; Huang WW; Huang WC; Lu CC; Chiang JH; Peng SF; Chung JG; Lin YH; Hsu YM; Amagaya S; Yang JS
Int J Oncol; 2012 Dec; 41(6):2065-72. PubMed ID: 23008020
[TBL] [Abstract][Full Text] [Related]
36. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
37. p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells.
Kim MS; Lee EJ; Kim HR; Moon A
Cancer Res; 2003 Sep; 63(17):5454-61. PubMed ID: 14500381
[TBL] [Abstract][Full Text] [Related]
38. [Study on the inhibiting effects of equol on MCF-7 cells proliferation and its molecular mechanisms].
Wang M; Ren G
Wei Sheng Yan Jiu; 2014 Jan; 43(1):11-5. PubMed ID: 24564104
[TBL] [Abstract][Full Text] [Related]
39. ERK/MAPK regulation of the androgen responsiveness of breast cancer cells.
Azzam DG; Tay JW; Greeve MA; Harvey JM; Bentel JM
Adv Exp Med Biol; 2008; 617():429-35. PubMed ID: 18497066
[TBL] [Abstract][Full Text] [Related]
40. Pseudolaric acid B induces endometrial cancer Ishikawa cell apoptosis and inhibits metastasis through AKT-GSK-3β and ERK1/2 signaling pathways.
Wang D; Tian Y; Feng W; Zhao L; Zhao M; Liu J; Wang Q
Anticancer Drugs; 2017 Jul; 28(6):603-612. PubMed ID: 28422767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
